Background Pharmacotherapy provides an option for adults with overweight and obesity to reduce their bodyweight if lifestyle modifications fail. We summarised the latest evidence for …
A Iannone, P Natale, SC Palmer… - Diabetes, Obesity …, 2023 - Wiley Online Library
Aim To compare the benefits and harms of drugs approved for weight management in adults with obesity or overweight. Materials and Methods We performed a systematic review of …
RS Padwal, D Rucker, SK Li… - Cochrane Database …, 2003 - cochranelibrary.com
Long‐term pharmacotherapy for obesity and overweight - Padwal, RS - 2003 | Cochrane Library Skip to Content Cookies Our site uses cookies to improve your experience. You can …
P Manjoo, AM Sharma - The Lancet, 2023 - thelancet.com
The OASIS 1 trial by Filip K Knop and colleagues1 demonstrates the greatest magnitude of weight loss to date among oral anti-obesity medications. 2− 4 In this randomised, double …
FK Knop, VR Aroda, RD do Vale, T Holst-Hansen… - The Lancet, 2023 - thelancet.com
Background We assessed the efficacy and safety of the oral glucagon-like peptide-1 analogue, semaglutide 50 mg, taken once per day versus placebo for the treatment of …
TLR Health–Europe - The Lancet Regional Health-Europe, 2024 - ncbi.nlm.nih.gov
The landscape of pharmacological interventions in combating obesity has long struggled with the formidable challenge of balancing efficacy and safety, with weightloss drugs often …
M Lee, BN Lauren, T Zhan, J Choi… - Obesity Science & …, 2020 - Wiley Online Library
Summary Background The Food and Drug Administration has approved several pharmacotherapies for the treatment of obesity. This study assesses the cost‐effectiveness …
Background Obesity is a major public health issue, and new pharmaceuticals for weight management are needed. Therefore, we evaluated the efficacy and safety of the glucagon …
W Nuffer, JM Trujillo, J Megyeri - Annals of …, 2016 - journals.sagepub.com
Objective: To review and compare the phase 3 clinical trial evidence on the 4 new pharmacological agents approved for the management of overweight and obesity. Data …